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In an article in the previous issue of Critical Care, 
Schöchl and colleagues suggested that, in trauma 
patients, a hemostatic strategy combining the use of 
ﬁ   brino  gen concentrates or prothrombin complex con-
cen trates (PCCs) (or both) guided by thromboelastometry 
resulted in a reduction of exposure to allogeneic blood 
products when compared with a strategy using fresh 
frozen plasma (FFP) guided by standard coagulation 
assays [1]. Th   e primary concern with this analysis is the 
comparison of a series of patients treated at a single 
center with a highly protocolized approach to transfusion 
against a registry-based cohort of patients from multiple 
centers with no standardized protocol. Also, several very 
speciﬁ   c biases introduced into the analysis are of 
concern. First, the time required to obtain a hemostatic 
result varied greatly between groups, ranging from less 
than 15 minutes with the rotation thrombelastography 
(ROTEM) to usually more than 45 to 60 minutes in the 
standard group [2]. Th   e timing of coagulation component 
replacement must be factored into this analysis. Th  e 
second bias centers around the concentration of ﬁ  brino-
gen delivered: 3 g of ﬁ  brinogen (median of 6 units of FFP) 
in the FFP group versus a median of 6 g in the ﬁ  brinogen-
PCC group. Previous reports have demonstrated a close 
relationship between blood loss and ﬁ  brinogen  level 
[3,4].
Finally, it should be noted that thromboelastometry is 
not mandatory for the use of PCC and ﬁ  brinogen [5]. 
Although the use of thromboelastometry and a 
hemostatic strategy combining ﬁ   brinogen and PCC is 
very attractive, further controlled studies will have to 
determine which part of this strategy is really eﬀ  ective: 
early detection of coagulopathy or a combination of 
hemostatic factors or both?
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We thank David and colleagues for their comments. We 
acknowledged in our paper that there are limitations to 
the comparison of patients treated in one center 
according to a protocol with those from multiple centers 
with no standardized protocol. Th   us, our results are not 
as robust as those from randomized controlled trials but 
do represent the only published controlled study of 
combined ﬁ  brinogen concentrate and PCC in trauma.
David and colleagues described two biases, which 
relate to diﬀ  erences in time taken to obtain hemostatic 
results and ﬁ   brinogen dose. However, these are not 
biases. Instead, they represent inherent diﬀ  erences 
between the two treatment approaches and their inclu-
sion ensures that the study is applicable to clinical 
practice. Th   e point regarding ﬁ  brinogen dose is interest-
ing as the dose of FFP required to increase the ﬁ  brinogen 
level by a certain amount is dependent on the starting 
point. Much higher volumes are needed to increase the 
ﬁ  brinogen level from 1 to 1.5 g/L compared with 0.5 to 
1.0 g/L. Th   e dose-response curve for ﬁ  brinogen adminis-
tered via FFP is not linear, and the required dose increases 
exponentially as the target level approaches 2 g/L, which 
is the mean concentration in FFP [6].
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© 2011 BioMed Central LtdDavid and colleagues comment that use of thrombo-
elastometry is not mandatory. Although this is true, the 
risk-beneﬁ  t proﬁ  le of coagulation factor concentrates can 
almost certainly be improved by thromboelastometry. In 
thromboelastometry (in contrast to ﬁ  xed-dose therapy), 
assessment of the patient’s coagulation status before 
treatment and monitoring of the post-treatment response 
(feedback loop) allow under- or over-treatment to be 
avoided.
Th  e improvements reported in our study are attribu-
table to changes in both therapy and diagnostics. We 
agree that it would be interesting to prospectively assess 
the relative contributions of these two aspects.
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